Drug intelligence / Profile preview

TJ0113

Development stage: Phase 3
Lead developer: Hangzhou Tianji Jishi Biotechnology
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

TJ0113 is a small molecule selective mitophagy inducer developed by Hangzhou PhecdaMed. It acts by activating the PINK1/Parkin pathway to enhance mitophagy activity and restore mitochondrial integrity. The drug is currently being evaluated in Phase 2 clinical trials for various indications, including Parkinson's disease, depressive disorder, and age-related hearing loss. Preclinical evidence also suggests potential efficacy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) by attenuating renal fibrosis, inflammation, and cyst growth through improved mitochondrial quality control.

Other names: TJ0113 capsulesTJ-0113 capsulesTJ 0113 capsules

Targets

PINK1 (Serine/threonine-protein kinase PINK1, mitochondrial)PRKN (E3 ubiquitin-protein ligase parkin)

Beyond the preview

Go deeper on TJ0113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ0113.

Explore the full profile